In the future, a combinational design including anti-CD47 antibody with appropriate chemotherapy and immune-modulating agents such as anti-tumor antibodies, type I IFN, STING agonists, immune checkpoint modulators, and others should be intensely investigated for achieving synergistic and tumor-specific effect for clinical application. The gene discussed is STING1; the disease is neoplasm.